DCM Advisors LLC Has $5.13 Million Stock Position in AbbVie Inc. (NYSE:ABBV)

DCM Advisors LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 3.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,873 shares of the company’s stock after acquiring an additional 1,078 shares during the period. AbbVie comprises about 2.4% of DCM Advisors LLC’s holdings, making the stock its 17th largest holding. DCM Advisors LLC’s holdings in AbbVie were worth $5,131,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Fiduciary Advisors Inc. purchased a new stake in AbbVie in the 4th quarter worth about $29,000. EnRich Financial Partners LLC raised its stake in shares of AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company’s stock worth $29,000 after purchasing an additional 110 shares in the last quarter. Promus Capital LLC purchased a new stake in shares of AbbVie during the 4th quarter worth about $30,000. Bradley & Co. Private Wealth Management LLC purchased a new stake in shares of AbbVie during the 4th quarter worth about $31,000. Finally, Prudent Man Investment Management Inc. purchased a new stake in shares of AbbVie during the 4th quarter worth about $32,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

ABBV opened at $181.74 on Thursday. The firm has a market capitalization of $321.02 billion, a P/E ratio of 75.72, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. The stock’s 50 day moving average price is $189.64 and its two-hundred day moving average price is $186.68. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $218.66.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $0.06. The firm had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The company’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.31 EPS. On average, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ABBV. Guggenheim raised their price target on AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. StockNews.com raised AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 28th. Bank of America raised their price target on AbbVie from $200.00 to $223.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 4th. Truist Financial raised their price target on AbbVie from $211.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Finally, BMO Capital Markets raised their price target on AbbVie from $208.00 to $215.00 and gave the stock an “outperform” rating in a research note on Monday, February 3rd. Eight research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $210.95.

Insider Buying and Selling at AbbVie

In other news, EVP Timothy J. Richmond sold 29,917 shares of AbbVie stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the sale, the executive vice president now owns 44,284 shares of the company’s stock, valued at approximately $8,985,223.60. This trade represents a 40.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $210.08, for a total value of $12,359,426.56. Following the transaction, the executive vice president now owns 53,234 shares of the company’s stock, valued at $11,183,398.72. This trade represents a 52.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 107,693 shares of company stock valued at $22,282,985 in the last 90 days. 0.25% of the stock is currently owned by insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.